{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:58:00Z","timestamp":1767135480186,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006352","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000}}],"reference-count":130,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006352.pub2","type":"journal-article","created":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T07:32:20Z","timestamp":1374046340000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fluphenazine (oral) versus placebo for schizophrenia"],"prefix":"10.1002","author":[{"given":"Hosam E","family":"Matar","sequence":"first","affiliation":[{"name":"Northern General Hospital; Department of Trauma and Orthopaedics; Herries Road Sheffield UK S5 7AU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Qutayba","family":"Almerie","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust Royal Infirmary; Department of General Surgery; Beckett Street Leeds UK LS9 7TF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Sampson","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,17]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1176\/ajp.156.2.299","article-title":"Diazepam treatment of early signs of exacerbation in schizophrenia","volume":"156","author":"Carpenter","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/archpsyc.1971.01750170020004","article-title":"Drug treatment in newly admitted schizophrenic patients","volume":"25","author":"Clark","year":"1971","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archpsyc.1964.01720210028005","article-title":"Phenothiazine treatment in acute schizophrenia","volume":"10","author":"Cole","year":"1964","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/schbul\/11.3.390","article-title":"An empirical test of a kraepelinian vs. a bleulerian view of negative symptoms","volume":"11","author":"Gibbons","year":"1985","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.111.471.120","article-title":"Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment","volume":"111","author":"Goldberg","year":"1965","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archpsyc.1967.01730190109015","article-title":"Prediction of improvement in schizophrenia under four phenothiazines","volume":"16","author":"Goldberg","year":"1967","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0007|cit7","first-page":"S153","article-title":"Schizophrenic subtypes defined by response to drugs and placebo","volume":"29","author":"Goldberg","year":"1968","journal-title":"Diseases of the Nervous System"},{"issue":"6","key":"10.1002\/14651858.CD006352.pub2-BIB0008|cit8","first-page":"716","article-title":"Relationship between the hospital milieu and the response to phenothiazines in the treatment of schizophrenics","volume":"70","author":"Klerman","year":"1970","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1192\/bjp.110.467.531","article-title":"Thioproperazine in chronic schizophrenia","volume":"110","author":"Hordern","year":"1964","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/archpsyc.1994.03950040024003","article-title":"Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia","volume":"51","author":"Marder","year":"1994","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1192\/bjp.109.460.428","article-title":"A trial of fluphenazine in schizophrenia","volume":"109","author":"Millar","year":"1963","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0013|cit12","first-page":"40","article-title":"Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data","volume":"13","author":"Rifkin","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0012|cit13","first-page":"499","article-title":"The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics","volume":"14","author":"Rifkin","year":"1979","journal-title":"Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD006352.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archpsyc.1977.01770220097011","article-title":"Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data","volume":"34","author":"Rifkin","year":"1977","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0015|cit15","first-page":"24","article-title":"Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics","volume":"12","author":"Rifkin","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1977.01770130045004","article-title":"Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year","volume":"34","author":"Rifkin","year":"1977","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006352.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"Vitamin E treatment for tardive dyskinesia","volume":"56","author":"Adler","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0006-3223(94)91073-1","article-title":"Vitamin E treatment of TD: development of a VA cooperative study","volume":"35","author":"Adler","year":"1994","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002130050320","article-title":"Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study 394","volume":"132","author":"Caligiuri","year":"1997","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0020|cit20","first-page":"84","article-title":"Controlled trials of an amitriptyline-fluphenazine combination in depressive neuroses and psychoses: a collaborative study","volume":"12","author":"Baldini","year":"1970","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0022|cit21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000418016","article-title":"Treatment of positive and negative symptoms: pharmacologic approaches","volume":"24","author":"Boyer","year":"1990","journal-title":"Modern Problems of Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1192\/bjp.166.1.68","article-title":"Treatment of negative symptoms in schizophrenia with amisulpride","volume":"166","author":"Boyer","year":"1995","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0024|cit23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1017\/S0767399X0000095X","article-title":"Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools","volume":"2","author":"Boyer","year":"1987","journal-title":"Psychiatrie and Psychobiologie"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0023|cit24","first-page":"321","article-title":"Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results","volume":"3","author":"Boyer","year":"1988","journal-title":"Annales de Psychiatrie"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0025|cit25","unstructured":"Lecrubier Y Amisulpride in deficit schizophrenia 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France 1997 7894879"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006352.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00004850-199705002-00005","article-title":"Clinical update on amisulpride in deficit schizophrenia","volume":"12","author":"Rein","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1176\/ajp.144.12.1549","article-title":"Neuroleptic responsivity of negative and positive symptoms in schizophrenia","volume":"144","author":"Breier","year":"1987","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0920-9964(92)90127-Q","article-title":"Novel neuroleptic dosage reduction strategies","volume":"6","author":"Carpenter","year":"1992","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006352.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0010-440X(72)90055-7","article-title":"Work study in the assessment of the effects of phenothiazines in schizophrenia","volume":"13","author":"Chacon","year":"1972","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1973.tb04399.x","article-title":"Clinical and work performance variables in phenothiazine therapy of schizophrenia","volume":"49","author":"Chacon","year":"1973","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0031|cit31","first-page":"20","article-title":"Clinical effectiveness of oral and parenteral rapid neuroleptization","volume":"48","author":"Coffman","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0033-3182(75)71232-X","article-title":"Prevention of recidivism of schizophrenics treated with fluphenazine enanthate","volume":"16","author":"Giudice","year":"1975","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archpsyc.1990.01810180058009","article-title":"Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with Schizophrenia","volume":"47","author":"Doran","year":"1990","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2466\/pms.1963.17.2.511","article-title":"Effect of phenothiazines on the thinking of acute schizophrenics","volume":"17","author":"Downing","year":"1963","journal-title":"Perceptual and Motor Skills"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0893-133X(98)00047-5","article-title":"Mechanism of peripheral noradrenergic stimulation by clozapine","volume":"20","author":"Elman","year":"1999","journal-title":"Neuropyschopharmacology"},{"issue":"512","key":"10.1002\/14651858.CD006352.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1192\/bjp.114.512.837","article-title":"A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics","volume":"114","author":"Haider","year":"1968","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0037|cit37","first-page":"171","article-title":"Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine","volume":"31","author":"Hanlon","year":"1970","journal-title":"Diseases of the Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0022-3956(70)90008-7","article-title":"Effect of phenothiazines on reaction time in schizophrenics","volume":"7","author":"Held","year":"1970","journal-title":"Journal of Psychiatric Research"},{"issue":"12","key":"10.1002\/14651858.CD006352.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archpsyc.1979.01780120013001","article-title":"Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride","volume":"36","author":"Hogarty","year":"1979","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0040|cit40","first-page":"173","article-title":"Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy","volume":"2","author":"Holden","year":"1970","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00005053-196106000-00007","article-title":"A comparison of fluphenazine, trifluoperazine and a placebo in the context of an active treatment unit","volume":"132","author":"Howell","year":"1961","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0447.1971.tb03701.x","article-title":"Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment","volume":"47","author":"Itil","year":"1971","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005053-197503000-00005","article-title":"Computerized EEG: predictor of outcome in schizophrenia","volume":"160","author":"Itil","year":"1975","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archpsyc.1982.04290010048009","article-title":"Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1176\/ajp.119.8.779","article-title":"A new method of drug therapy","volume":"119","author":"Kinross-Wright","year":"1963","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0046|cit46","first-page":"66","article-title":"A controlled study of a very long-acting phenothiazine preparation","volume":"1","author":"Kinross-Wright","year":"1964","journal-title":"International Journal of Neuropsychiatry"},{"issue":"854","key":"10.1002\/14651858.CD006352.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.1.5854.633","article-title":"Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry","volume":"1","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"issue":"775","key":"10.1002\/14651858.CD006352.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bmj.3.5775.599","article-title":"Trial of maintenance therapy in schizophrenia","volume":"3","author":"Leff","year":"1971","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0920-9964(94)90068-X","article-title":"Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia","volume":"12","author":"Litman","year":"1994","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0050|cit50","first-page":"479","article-title":"Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine","volume":"25","author":"Marder","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0920-9964(93)90597-C","article-title":"Psychosocial and pharmacological strategies for maintenance therapy: effects on two - year outcome","volume":"9","author":"Marder","year":"1993","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1600-0447.1975.tb00220.x","article-title":"Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population","volume":"51","author":"Martin","year":"1975","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0053|cit53","first-page":"105","article-title":"Clinical effects of fluphenazine dihydrychloride in chronic schizophrenia","volume":"3","author":"Matheu","year":"1961","journal-title":"Journal of Neuropsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0054|cit54","first-page":"445","article-title":"Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives","volume":"19","author":"Mattes","year":"1984","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000418016","article-title":"Treatment of positive and negative symptoms: pharmacologic approaches","volume":"24","author":"Boyer","year":"1990","journal-title":"Modern Problems of Pharmacopsychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1017\/S0767399X0000095X","article-title":"Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools","volume":"2","author":"Boyer","year":"1987","journal-title":"Psychiatrie and Psychobiologie"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0057|cit57","first-page":"312","article-title":"A double blind, controlled, multicenter trial of low dose amisulpride (Solian(R) 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia","volume":"3","author":"Pichot","year":"1988","journal-title":"Annales de Psychiatrie"},{"issue":"7","key":"10.1002\/14651858.CD006352.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.1986.01800070059008","article-title":"Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment","volume":"43","author":"Pickar","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl B","key":"10.1002\/14651858.CD006352.pub2-BIB0059|cit59","first-page":"129","article-title":"Predictors of clozapine response in schizophrenia","volume":"55","author":"Pickar","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archpsyc.1992.01820050009001","article-title":"Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine","volume":"49","author":"Pickar","year":"1992","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006352.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archpsyc.1978.01770310095007","article-title":"Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics","volume":"35","author":"Quitkin","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hup.470070405","article-title":"Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels","volume":"7","author":"Sampath","year":"1992","journal-title":"Human Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0063|cit63","first-page":"642","article-title":"A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate","volume":"23","author":"Schlosberg","year":"1978","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/ajp.136.2.217","article-title":"Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate","volume":"136","author":"Gelenberg","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0065|cit65","first-page":"483","article-title":"Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study","volume":"24","author":"Levine","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archpsyc.1982.04290020051010","article-title":"Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics","volume":"39","author":"Mandel","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0070|cit67","first-page":"29","article-title":"Dosage and side effect comparisons between oral and depot fluphenazine","volume":"13","author":"Schooler","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0067|cit68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0041-1723921","article-title":"The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine","volume":"9","author":"Schooler","year":"1976","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0069|cit69","first-page":"44","article-title":"Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen","volume":"15","author":"Schooler","year":"1979","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0068|cit70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archpsyc.1980.01780140018002","article-title":"Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate","volume":"37","author":"Schooler","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3371\/CSRP.3.2.4","article-title":"Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia","volume":"3","author":"Shafti","year":"2009","journal-title":"Clinical Schizophrenia and Related Psychoses"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-198105000-00005","article-title":"Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics","volume":"1","author":"Shenoy","year":"1981","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006352.pub2-BIB0073|cit73","first-page":"470","article-title":"A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse","volume":"55","author":"Steingard","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0074|cit74","first-page":"792","article-title":"The social value of fluphenazine decanoate","volume":"76","author":"Stevens","year":"1976","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.2042-7158.1966.tb07825.x","article-title":"A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency","volume":"18","author":"Turner","year":"1966","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0076|cit76","first-page":"165","article-title":"A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients","volume":"73","author":"Praag","year":"1970","journal-title":"Psychiatria Neurologia Neurochirurgia"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0077|cit77","first-page":"149","article-title":"A comparison of fluphenazine, triflupromazine, and phenobarbital in the treatment of chronic schizophrenic patients: a double-blind controlled study","volume":"23","author":"Vestre","year":"1962","journal-title":"Journal of Clinical and Experimental Psychopathology"},{"issue":"8098","key":"10.1002\/14651858.CD006352.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0140-6736(78)92361-9","article-title":"Maintenance drugs for schizophrenia","volume":"2","author":"Watt","year":"1978","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0080|cit79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1981.tb00761.x","article-title":"A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients","volume":"64","author":"Wistedt","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD006352.pub2-BIB0081|cit80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archpsyc.1982.04290060085019","article-title":"Neuroleptics and depression","volume":"39","author":"Wistedt","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0079|cit81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006352.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00427950","article-title":"A depot neuroleptic withdrawal study neurological effects","volume":"80","author":"Wistedt","year":"1983","journal-title":"Psychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD006352.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0006-3223(93)90250-H","article-title":"Autonomic effects of clozapine in schizophrenia - comparison with placebo and fluphenazine","volume":"34","author":"Zahn","year":"1993","journal-title":"Biological Psychiatry"},{"issue":"14","key":"10.1002\/14651858.CD006352.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"10.1002\/14651858.CD006352.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/archpsyc.55.8.754","article-title":"Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study","volume":"55","author":"Ahmed","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0088|cit88","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1943-278X.1992.tb01040.x","article-title":"Schizophrenia - a high-risk factor for suicide: clues to risk reduction","volume":"22","author":"Caldwell","year":"1992","journal-title":"Suicide and Life-Threatening Behavior"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0090|cit90","first-page":"167","article-title":"Fluphenazine: a preliminary study","volume":"20","author":"Darling","year":"1959","journal-title":"Disease of the Nervous System"},{"issue":"1Suppl","key":"10.1002\/14651858.CD006352.pub2-BIB0091|cit91","first-page":"2S","article-title":"The natural course of schizophrenia and effective maintenance drug therapy","volume":"6","author":"Davis","year":"1986","journal-title":"Journal of Clincal Psychopharmacology"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0092|cit92","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"(supp 279)","key":"10.1002\/14651858.CD006352.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1980.tb07084.x","article-title":"Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study","volume":"61","author":"Dencker","year":"1980","journal-title":"Acta Psychiatria Scandinavica"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD006352.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD006352.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/00004647-200108000-00011","article-title":"Quantification of neuroreceptors in living human brain v. endogenous neurotransmiter inhibition of haloperidol binding in psychosis","volume":"21","author":"Gjedde","year":"2001","journal-title":"Journal of Cerebral Blood Flow Metabolism"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0101|cit101","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"issue":"8983","key":"10.1002\/14651858.CD006352.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(95)91801-9","article-title":"Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients","volume":"346","author":"Hietala","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0104|cit104","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] The Cochrane Library 2005"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0105|cit105","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD006352.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1176\/ajp.117.2.157","article-title":"Preliminary results with fluphenazine (prolixin) in chronic psychotic patients","volume":"117","author":"Holt","year":"1960","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006352.pub2-BIB0107|cit107","first-page":"1092","article-title":"Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study","volume":"22","author":"Jablensky","year":"1992","journal-title":"Psychological Medicine Monograph Suppl."},{"issue":"suppl 5","key":"10.1002\/14651858.CD006352.pub2-BIB0108|cit108","first-page":"30","article-title":"Depot neuroleptics: A comparison review of standard, intermediate and low-dose regimens","volume":"47","author":"Kane","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0109|cit109","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2-3","key":"10.1002\/14651858.CD006352.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0006-3223(99)00109-2","article-title":"Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET","volume":"46","author":"Lindstrom","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0114|cit114","first-page":"19","volume-title":"The Multidimensional Scale for Rating Psychiatric Patients","author":"Lorr","year":"1953"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006352.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"Reduced prefronatal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nature Neuroscience"},{"issue":"12","key":"10.1002\/14651858.CD006352.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0119|cit119","volume-title":"Modern Psychmetrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD006352.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"For the CONSORT Group.\u00a0CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"152","author":"Schulz","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.317.7167.1181","article-title":"Content and quality of 2000 controlled trials in schizophrenia over 50 years","volume":"317","author":"Thornley","year":"1998","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD006352.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0125|cit125","unstructured":"Essential Medicines. WHO Model List. 14th Edition http:\/\/whqlibdoc.who.int\/hq\/2005\/a87017_eng.pdf"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0126|cit126","unstructured":"Wikipedia (The Free Encyclopedia) http:\/\/en.wikipedia.org\/wiki\/Fluphenazine#Pharmacokinetics Accessed in Nov 2006"},{"key":"10.1002\/14651858.CD006352.pub2-BIB0127|cit127","unstructured":"Psychotropics http:\/\/www.psychotropics.dk\/"},{"issue":"7","key":"10.1002\/14651858.CD006352.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006352","article-title":"Oral fluphenazine versus placebo for schizophrenia","author":"Matar","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006352.pub2-BIB0130|cit130","first-page":"8","article-title":"Oral fluphenazine versus placebo for schizophrenia: A Cochrane systematic review of 40 years of randomised controlled trials.","volume":"36","author":"Matar","year":"2007","journal-title":"Revista Colombiana de Psiquiatria"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006352.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006352.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T17:33:19Z","timestamp":1715707999000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006352.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,17]]},"references-count":130,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006352.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,17]]}}}